TARLATAMAB YA ES EL NUEVO TRATAMIENTO ESTÁNDAR DE SEGUNDA LINEA SMALL CELL LUNG CANCER EXTENSIVE-STAGE ... PARECE EVIDENTE QUE TARLATAMAB PODRÍA SER EL NUEVO PARADIGMA EN TODAS LAS LÍNEAS DE TRATAMIENTO SCLC-ES INCLUIDA LA DE MANTENIMIENTO ... EN LA QUE YA ESTÁ EN PLENA FASE III COMBINADO CON ATEZOLIZUMAB DE ROCHE ... Y ADEMÁS CUENTA CON EL STATUS DE ORPHAN DRUG EN ESTADOS UNIDOS .
22 noviembre 2012
Yondelis , Cientificos Italianos dan a Conocer , en la Prestigisa revista Oncologica EJC del Mes de Noviembre , Resultados que podrían tener " Importantes Implicaciones Clinicas " en Pacientes ( Tiroides /// Colón ) con un Nivel Alto de HMGA .
The Impairment of the High Mobility Group A (HMGA) Protein Function Contributes to the Anticancer Activity of Trabectedin .
EJC . Published Online , 13 November 2012.
... We first report that trabectedin has a higher cytotoxic effect on thyroid and colon carcinoma cells expressing abundant levels of HMGAs in comparison with cells not expressing them. Then, we have shown that trabectedin treatment displaces HMGA proteins from the HMGA-responsive promoters, including ATM promoter, impairing their transcriptional activity. Finally, we report a synergism between Ionising Radiations and trabectedin treatment restricted to the HMGA-overexpressing cancer cells. This result might have important clinical implications since it would suggest the use of trabectedin for the treatment of neoplasias expressing abundant HMGA levels that are frequently associated to chemoresistance and poor prognosis.
...